ascopubs.org

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...
Medscape

First Evidence: Targeted Melanoma Therapy May Change the Landscape of Treatment

Raf kinases are components of the MAP kinase pathway, a signal transduc-tion pathway that normally controls cell growth and division downstream of activated cell surface growth factor receptors. RAF1, ...
ascopubs.org

Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National ...

Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies As there were no previous pediatric data, ulixertinib was initially tested in a dose escalation cohort to establish the ...
Seeking Alpha

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...